Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

被引:9
作者
Li, Zheng [1 ,2 ]
Wang, Jun [1 ,2 ]
Ge, Shuai-Shuai [1 ,2 ]
Qiu, Qiao-Cheng [1 ,2 ]
Du, Jia-Hui [3 ]
Shan, Shuang-Shuang [3 ]
Shen, Xiang-Dong [1 ,2 ]
Wan, Chao-Ling [1 ,2 ]
Wang, Bin-Ru [1 ,2 ]
Wu, De-Pei [1 ,2 ]
Qiu, Hui-Ying [1 ,2 ]
Xue, Sheng-Li [1 ,2 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou, Peoples R China
[3] Suzhou Vocat Hlth Coll, Suzhou Key Lab Med Biotechnol, Suzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
venetoclax; azacitidine; midostaurin; t(8; 21); relapsed acute myeloid leukemia; KIT mutation; targeted therapy; MUTATIONS; CANCER; ADULTS;
D O I
10.3389/fonc.2022.841276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhibitor. The venetoclax+HMA strategy is also a notable salvage regimen that achieves good clinical outcomes in the treatment of relapsed or refractory (R/R) AML. However, in our clinical practice, we found that disease progressed rapidly even after venetoclax+azacitidine (AZA) therapy in two relapsed t(8;21) AML patients with KIT mutations. We report for the first time the therapeutic potential of venetoclax+midostaurin as a new combination therapy for relapsed t(8;21) AMLs with KIT mutations showing resistance to venetoclax+AZA therapy. Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. Our study shows that the venetoclax+midostaurin regimen may be a promising treatment option for R/R t(8;21) AML with KIT mutations.
引用
收藏
页数:6
相关论文
共 35 条
[31]   Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL-rearranged complex karyotype acute myeloid leukemia [J].
Edahiro, Taro ;
Ureshino, Hiroshi ;
Chishaki, Ren ;
Fujino, Keita ;
Mino, Tatsuji ;
Yoshida, Tetsumi ;
Fukushima, Noriyasu ;
Ichinohe, Tatsuo .
EJHAEM, 2023, 4 (01) :273-275
[32]   RUNX1/ETO and mutant KIT both contribute to programming the transcriptional and chromatin landscape in t(8;21) acute myeloid leukemia [J].
Chin, Paulynn Suyin ;
Assi, Salam A. ;
Ptasinska, Anetta ;
Imperato, Maria Rosaria ;
Cockerill, Peter N. ;
Bonifer, Constanze .
EXPERIMENTAL HEMATOLOGY, 2020, 92 :62-74
[33]   Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases [J].
Wang, Qingwei ;
Hu, Yixin ;
Gao, Li ;
Zhang, Senlin ;
Lu, Jun ;
Li, Bohan ;
Li, Jie ;
Yao, Yanhua ;
Cheng, Shengqin ;
Xiao, Peifang ;
Hu, Shaoyan .
ANNALS OF HEMATOLOGY, 2024, 103 (09) :3795-3800
[34]   Successful Treatment With Venetoclax Plus Azacytidine Combined With Radiation Therapy and Donor Lymphocyte Infusion in a Patient With Extramedullary Relapse of Acute Myeloid Leukemia After Stem Cell Transplantation [J].
Shirato, Shotaro ;
Iyama, Satoshi ;
Fujimi, Akihito ;
Takahashi, Satoshi ;
Kobune, Masayoshi .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
[35]   Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis [J].
Yu, Guopan ;
Yin, Zhao ;
Yao, Zurong ;
Nie, Xiaqi ;
Jin, Hua ;
Zhang, Yu ;
Xu, Dan ;
Jiang, Xuejie ;
Ping, Baohong .
BLOOD, 2023, 142